anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: In end stage renal disease )ESRD(, reduced EPO production resulted in decreased oxygen diffusion that cause Hypoxia-inducible factors (HIFs) stabilization. The mechanism of beneficial effects of H2S in chronic kidney disease (CKD) is the aim of the present study to examine the effects of the H2S donor sodium hydrosulfide (NaHS) on renal function parameters, oxidative stress indices and expression levels of HIF-2α gene and erythropoietin protein in 5/6 nephrectomy-induced chronic renal failure in rats.
METHODS AND MATERIALS: Male rats were assigned into 3 groups (n = 8): Sham, CKD and NaHS groups. In the CKD group, 5/6 nephrectomy was performed. In the sham group, rats were anesthetized but 5/6 nephrectomy was not induced. In the NaHS group, 30 µmol/L of NaHS in drinking water for 8 weeks was adminstrated 4 weeks after 5/6 nephrectomy induction. At the end of the 12 week, blood and renal tissues were taken to evaluate renal function parameters, oxidative stress indices and expression levels of HIF-2α gene and erythropoietin protein.
RESULTS: The induction of 5/6 nephrectomy significantly caused renal dysfunction, oxidative stress, increased HIF-2α gene expression and decreased erythropoietin levels in renal tissue samples. NaHS administration resulted in a marked improvement in renal function and oxidative stress indicators, a marked reduction in HIF-2α gene expression as well as an increase in erythropoietin protein levels in comparison with the CKD group.
CONCLUSION: In this study, regional hypoxia and oxidative stress in CKD, may cause the stabilization of the HIFs complexes, although erythropoietin synthesis was not increased due to destructive effects of CKD on the kidney tissues. Administration of NaHS caused up-regulating HIF-erythropoietin signaling pathway.
BACKGROUND: Systemic allergic reactions (sARs) following coronavirus disease 2019 (COVID-19) mRNA vaccines were initially reported at a higher rate than after traditional vaccines.
OBJECTIVE: We aimed to evaluate the safety of revaccination in these individuals and to interrogate mechanisms underlying these reactions.
METHODS: In this randomized, double-blinded, phase 2 trial, participants aged 16 to 69 years who previously reported a convincing sAR to their first dose of COVID-19 mRNA vaccine were randomly assigned to receive a second dose of BNT162b2 (Comirnaty) vaccine and placebo on consecutive days in a blinded, 1:1 crossover fashion at the National Institutes of Health. An open-label BNT162b2 booster was offered 5 months later if the second dose did not result in severe sAR. None of the participants received the mRNA-1273 (Spikevax) vaccine during the study. The primary end point was recurrence of sAR following second dose and booster vaccination; exploratory end points included biomarker measurements.
RESULTS: Of 111 screened participants, 18 were randomly assigned to receive study interventions. Eight received BNT162b2 second dose followed by placebo; 8 received placebo followed by BNT162b2 second dose; 2 withdrew before receiving any study intervention. All 16 participants received the booster dose. Following second dose and booster vaccination, sARs recurred in 2 participants (12.5%; 95% CI, 1.6 to 38.3). No sAR occurred after placebo. An anaphylaxis mimic, immunization stress-related response (ISRR), occurred more commonly than sARs following both vaccine and placebo and was associated with higher predose anxiety scores, paresthesias, and distinct vital sign and biomarker changes.
CONCLUSIONS: Our findings support revaccination of individuals who report sARs to COVID-19 mRNA vaccines. Distinct clinical and laboratory features may distinguish sARs from ISRRs.
Single-arm study with patients receiving Everolimus orally once daily dosing of 10 mg continuously from Day 1 of study until progression of disease or unacceptable toxicity. In addition archival tissue will be analysed for markers of P13K/mTOR pathway activation.
Randomization order tracking will be done with sequentially numbered containers. Patients participating in the study will be blinded to which treatment group they will be included in. Before the study, written and verbal "Informed Consent Form" will be obtained from all participants who meet the inclusion criteria. After the sociodemographic and clinical features of the participants are recorded, the cognitive status of the patients will be evaluated with MMT. Participants' neck proprioceptive senses, cervical proprioceptive awareness, cervical joint failure test, falling risks, dynamic and static balance tests on the Tecnobody Prokin 252 Isokinetic Balance Platform, among objective tests, Timed up and go test and Berg balance test, among clinical tests, and their fear of falling, Modified. It will be evaluated with the Fall Effectiveness Scale. To avoid bias, evaluations will be made by a blind physiotherapist to the participants assigned to the groups. Tests; It will be done one day before the treatments to the patients in the study and control groups begin, and all evaluations will be repeated after the 4-week neurorehabilitation process is completed. All data obtained will be noted on a prepared evaluation form.
The invention discloses a new use of Eryngiolide A for curing rarefaction of bone. The rarefaction of bone is an important disease damaging human health, with aging of population, rarefaction of bone patients gradually increase, the rarefaction of bone causes huge burden on society, medical treatment and economy. Although relative experts and scholars at home and abroad attach great importance to prevent and cure the rarefaction of bone, the rarefaction of bone still lacks effective curing medicines. The fact that the Eryngiolide A has evident rarefaction of bone resisting function is discovered through in vivo test. Experiment results show that the Eryngiolide A can inhibit strengthening of bone conversion rate caused by ovariectomizing, reduce bone destruction, meanwhile can improve blood calcium concentration, and is benefit for deposition of bones. The Eryngiolide A has therapeutic effect on the deposition of rarefaction of bone caused by lack of the antiestrogen, and has no estrogen side effect.
Diabetes mellitus is a chronic disease that is associated with altered metabolism of the inositol sugars myo-inositol (MI) and D-chiro-inositol (DCI). In animals, catabolism of MI and DCI depends on the enzyme myo-inositol oxygenase (MIOX), which catalyzes the first committed step of the glucuronate-xylulose pathway, and is found almost exclusively in the kidneys. The crystal structure of MIOX, in complex with MI, has been determined by multiwavelength anomalous diffraction methods and refined at 2.0-A resolution (R = 0.208, Rfree = 0.258). The structure reveals a monomeric, single-domain protein with a mostly-helical fold that is distantly related to the diverse HD domain superfamily. Five helices form the structural core and provide six ligands (4 His and 2 Asp) for the di-iron center, in which the two iron atoms are bridged by a putative hydroxide ion and one of the aspartate ligands, Asp124. A key loop forms a lid over the MI substrate, which is coordinated in bidentate mode to one iron atom. It is proposed that this mode of iron coordination, and interaction with a key lysine residue, activate MI for bond cleavage. The structure also reveals the basis of substrate specificity and suggests routes for the development of specific MIOX inhibitors for treatment of inositol-associated disorders.
14,101. Matweff, R. June 16. Disinfectants; medicinal powders for external use. - A material for use in filling teeth and having disinfecting properties is obtained by carbonizing a mixture of resinous pine-bark with straw or cellulose, or with both, in an enclosed vessel, so that the carbon absorbs the greater part of the other products. The mixture may be placed in contact with tobacco leaves before carbonizing. Suitable proportions are 5 parts bark, 3 parts straw, and 2 parts cellulose.
An increasing prevalence of Type 2 Diabetes is associated with the aging population, a significant rise in the prevalence of obesity, and a sedentary lifestyle. In Canada, 4.9-7.0% over the age of 12 and 17% over the age of 64 are estimated to have diabetes, 90-95% of which will be Type 2. Strong evidence supports the importance of physical activity in the management of Type 2 Diabetes. However, current literature lacks clear understanding of best strategies for physical activity behaviour change in this target population. Existing studies employ resource intensive, one-to-one individual and clinically-based approaches with limited theoretical grounding for recommended health behaviour change. Most fail to offer practical, sustainable, economically viable solutions, with documented long-term intervention efficacy. The call to move beyond the clinical focus by including theoretically population-based and "real-life" approaches for the management Type 2 Diabetes remains largely unheeded. The three interventions are: (1) standard print-based physical activity educational materials provided by the Canadian Diabetes Association (CDA); (2) CDA materials + pedometers and a log book + theoretical stage-matched print-based physical activity materials; and, (3) the same as intervention 2 with the addition of a 12-month physical activity telephone counseling protocol.
Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different COC.

Patient diaries from the clinical trial of Kaitlib Fe showed that on the first cycle of use, 37% of subjects taking Kaitlib Fe had unscheduled bleeding and/ or spotting. From Cycle 2 to 13, the percent of women with unscheduled bleeding/spotting ranged from 21 to 31% per cycle. For those women with unscheduled bleeding/spotting, the mean number of days of unscheduled bleeding/spotting was 5.2 in the first cycle of use and ranged from 3.6 to 4.2 in cycles 2 to 13. A total of 15 subjects out of 1,677 (0.9%) discontinued the study prematurely due to metrorrhagia or irregular menstruation.

Women who are not pregnant and use Kaitlib Fe may not have scheduled (withdrawal) bleeding every cycle or may experience amenorrhea (absence of any bleeding and spotting). The incidence of amenorrhea in the clinical trial increased from 8.1% of the subjects in Cycle 2 to 18.4% by Cycle 13. For those women who had scheduled (withdrawal) bleeding, the average duration of bleeding per cycle in Cycles 2 to 13 was 3.7 days.

If the patient has not adhered to the prescribed dosing schedule (missed one or more active tablets or started taking them on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and take appropriate diagnostic measures. If the patient has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy.

Some women may encounter amenorrhea or oligomenorrhea after stopping COCs, especially when such a condition was pre-existent.
Based on results of clinical trials, ribavirin monotherapy is not effective for the treatment of chronic hepatitis C virus infection; therefore, ribavirin capsules must not be used alone. The safety and efficacy of ribavirin capsules have only been established when used together with INTRON A or PegIntron (not other interferons) as combination therapy.

The safety and efficacy of ribavirin with INTRON A or PegIntron combination therapy for the treatment of HIV infection, adenovirus, RSV, parainfluenza, or influenza infections have not been established. Ribavirin capsules should not be used for these indications. 

There are significant adverse reactions caused by ribavirin/INTRON A or PegIntron combination therapy, including severe depression and suicidal or homicidal ideation, hemolytic anemia, suppression of bone marrow function, autoimmune and infectious disorders, pulmonary dysfunction, pancreatitis, and diabetes. Suicidal ideation or attempts occurred more frequently among pediatric patients, primarily adolescents, compared to adult patients (2.4% versus 1%) during treatment and off-therapy follow-up. Labeling for INTRON A and PegIntron should be reviewed in their entirety for additional safety information prior to initiation of combination treatment.
<P>PROBLEM TO BE SOLVED: To provide a composition which can efficiently be compounded with effectively acting ingredients at an optional rate under the consideration of a balance in a nutritive aspect, and is useful in the health aspect, while ocean deep water has been used for cosmetics or foods.  <P>SOLUTION: This composition is characterized by compounding marine mineral powder obtained from ocean deep water and shark fin powder in a desired ratio. The composition is compounded with other food materials in a desired amount to obtain the food. A cosmetic is characterized by compounding the composition with existing cosmetic materials. A nutritional supplement food is characterized by compounding the composition with the powder of a mixture of a deodorant with a binder material and then molding the mixture into tablets. When these are eaten or used, the good balanced nutrients can be taken in small amounts, and largely contribute to health maintenance.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Polyethers are prepared from (a) an aliphatic polyhydroxy compound having at least 3 hydroxy groups; and (b) and a ,b -alkylene oxide using an amine as catalyst, and in the presence of, as diluent, a polyether which is itself the product of the reaction of a compound (a) and a compound (b) in the presence of an amine. The polyhydroxy compound is partly suspended in the diluent at the start of the reaction. Water may be added to the reaction system. The preferred polyether products are those having 1 to 2 oxyalkylene groups per hydroxy group of the polyhydroxy compound.  Typical compounds (a) are sucrose, trimethylol ethane, di-pentaerythritol mannitol, glucose, and a -methyl glucoside, and sorbitol.  Typical compounds (b) are propylene, ethylene, 1,2- and 2,3-butylene, and styrene oxides. Suitable catalysts are those strongly basic secondary or tertiary amines which do not have an aryl group bonded to nitrogen e.g. N-methyl benzylamine, dimethylamine, trimethylamine, tri-n-propylamine, pyrrolidine, piperidine, 4-methylpiperidine, N - methyl and N - ethyl-piperidine piperazine, tetramethylguanidine, N,N,N1,N1 - tetramethylethylene, propylene, butylene or triethylene diamines, and alkanolamines e.g. N,N-dimethylethanolamine.  In the examples 1-6 and 8, various polyethers are prepared and used as diluents in the same reaction to prepare further amounts of similar polyethers.  In Example 7 a sorbitol/propylene oxide polyether is prepared and used as diluent in the preparation of a sucrose/propylene oxide condensate.
Once enrolled, all participants will receive behavioral weight loss treatment. Treatment will be 12 weeks in duration and will consist of 7 sessions. The content of sessions will provide the main elements described in behavioral therapy programs for obesity, based on empirical literature. Participants will be provided handouts, and the handout content will be based on our clinic treatment manual and published behavior therapy protocols. The program will be administered in individual 30-60-min sessions with a behavioral coach meeting every other week. This program emphasizes self-monitoring of food intake. It also emphasizes gradual weight loss, increasing physical activity, and improving diet through permanent lifestyle changes. Program topics include: self-monitoring of eating behavior, physical activity, changing the home environment and nutrition education. All treatment sessions will be conducted by licensed clinical health psychologists or psychology doctoral level students with experience in leading weight loss interventions.
<P>PROBLEM TO BE SOLVED: To provide a liquid for impregnating base fabric that has little irritation to skin, an excellent antiseptic effect derived from suppressed adsorption of an antiseptic to the base fabric and good appearance without white turbidity, and an impregnated product prepared by impregnating base fabric with the liquid.  <P>SOLUTION: The liquid for impregnating base fabric includes an antibacterial phospholipid and an anionic polymer in an amount of 100-1,000 pts.wt. of the anionic polymer to 100 pts.wt. of the antibacterial phospholipid. The impregnated product is prepared by using the liquid for impregnating base fabric.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Sick leave due to low back pain (LBP) is costly and compromises workforce productivity. Sick leave itself, fears and believes regarding return to work, and a low self-esteem have been identified as independent predictors of extended sick leave. Previous data suggested that multidisciplinary rehabilitation programs, including physical activities and psychobehavioral management, should decrease sick leave duration in chronic LBP. However these programs are heavy (at least 4 weeks long), and are often proposed to patients at the end of the management (over 6 months after the beginning of symptoms). Another approach could be to propose a shorter multidisciplinary program (for example 5 days long), earlier in the history of LBP to break the vicious circle as soon as possible. The target population could be people suffering from subacute LBP with sick leave duration between 4 and 24 weeks.
The invention relates to the isolation and characterization of a novel heat stable, autoclavable, microwaveable purified superoxide dismutase (SOD) isoenzyme, extracted from the leaves and rhizomes of Curcuma longa L. It has free radicals scavenging property and the scavenging activity remains intact before and after autoclaving (6-20 bars) upto 30min; heating (0-60 min at 30-1000°C) and microwaving (1-5 min). The form of SOD is stable with 33% of 02 scavenging activity remaining up to 6 days at room temperature (25-30 °C). The form is stable at least for 18 months at 4°C having 62% of the activity and 78% activity at -10 to -20°C containing 30% glycerol in a freezer without any infection or contamination. The enzyme has been purified by affinity chromatography. This isoenzyme of SOD has a molecular mass of 32 kDa under non-denaturing conditions with similar mass under denaturing conditions, thus, showing its monomeric nature.The inhibitor studies have shown that this isoform of the enzyme requires Cu/Zn as a co-factor and has antifungal, anti inflammatory and antibacterial properties. The method for the preparation of the purified isoenzyme of autoclavable superoxide dismutase and formulations containing the said autoclavable superoxide dismutase are given.
Asthma is a common chronic inflammatory disease of the airways, which affects millions of people worldwide. Arctiin, a bioactive molecule derived from the traditional Chinese Burdock, has not been previously reported for its effects on asthma in infants. In this study, an asthma model was established in mice by stimulation with ovalbumin (OVA). Bronchoalveolar lavage (BALF) was collected from OVA-challenged mice and the cells were counted. Lung tissue was harvested for hematoxylin-eosin (HE) staining and measurement of Wet/Dry weight ratios. The expressions of proteins were detected using enzyme-linked immunosorbent assay (ELISA) and Western blots. The superoxide dismutase (SOD) activity in lung tissue was measured using a commercial kit. We found that Arctiin had beneficial effects on asthma treatment. Firstly, it attenuated OVA-challenged lung pathological alterations. Secondly, it ameliorated pro-inflammatory response by reducing the number of inflammatory cells and mitigating the imbalance of Th1/Th2 factors in the bronchoalveolar lavage (BALF) of OVA-challenged mice. Importantly, Arctiin ameliorated OVA-induced lung tissue impairment and improved lung function. Additionally, we observed that oxidative stress (OS) in the pulmonary tissue of OVA-challenged mice was ameliorated by Arctiin. Mechanistically, Arctiin prevented OVA-induced activation of p38 and nuclear factor-κB (NF-κB). Based on these findings, we conclude that Arctiin might serve as a promising agent for the treatment of asthma.
BANZEL 200 mg tablets (containing 200 mg rufinamide) are pink in color, film-coated, oblong-shape tablets, with a score on both sides, imprinted with “ 262” on one side. They are available in bottles of 120 (NDC 62856-582-52).

BANZEL 400 mg tablets (containing 400 mg rufinamide) are pink in color, film-coated, oblong-shape tablets, with a score on both sides, imprinted with “ 263” on one side. They are available in bottles of 120 (NDC 62856-583-52).

BANZEL oral suspension is an orange flavored liquid supplied in a polyethylene terephthalate (PET) bottle with child-resistant closure. The oral suspension is packaged with a dispenser set which contains a calibrated oral dosing syringe and an adapter. Store the oral suspension in an upright position. Use within 90 days of first opening the bottle, then discard any remainder. The oral suspension is available in bottles of 460 mL (NDC 62856-584-46).
FIELD: medical engineering. SUBSTANCE: composition has suspension polyacrylate powder and liquid containing methyl metacrylate and acryl oligomers in mass proportion 2- 2.5:1-1.5. Mixture of ethoxylated dimethyl acrylate diphenylol propane, hexane diol 1,6-dimetacrylate, N-ethyl-N-phenyl-amino-2-hydroxypropyl metacrylate is applied as acryl oligomers. The mixture also contains polymethylsiloxane liquid. The ingredients are taken in known quantitative proportions. EFFECT: long service life and functional quality of dental prostheses. 1 tbl
For the management of endometriosis, the recommended duration of administration is 6 months. 

Currently, there are no clinical data on the effect of treatment of benign gynecological conditions with ZOLADEX for periods in excess of 6 months. 

Retreatment cannot be recommended for the management of endometriosis since safety data for retreatment are not available. If the symptoms of endometriosis recur after a course of therapy, and further treatment with ZOLADEX is contemplated, consideration should be given to monitoring bone mineral density. Clinical studies suggest the addition of Hormone Replacement Therapy (estrogens and/or progestins) to ZOLADEX is effective in reducing the bone mineral loss which occurs with ZOLADEX alone without compromising the efficacy of ZOLADEX in relieving the symptoms of endometriosis. The addition of Hormone Replacement Therapy may also reduce the occurrence of vasomotor symptoms and vaginal dryness associated with hypoestrogenism. The optimal drugs, dose and duration of treatment has not been established.